Last reviewed · How we verify
NCT07013851: NADIA
Clinical Trial to Assess the Efficacy of Dostarlimab as Neoadjuvant Therapy in Patients With MMRd/MSI-H Stage II-III Endometrial Cancer
Phase 2 trial testing Dostarlimab in MMRd/MSI-H Stage II-III Endometrial Cancer in 25 participants. Not yet recruiting.
1 March 2029
Quick facts
| Lead sponsor | Grupo Español de Investigación en Cáncer de Ovario |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 25 |
| Start date | 1 October 2025 |
| Primary completion | 1 March 2029 |
| Estimated completion | 1 October 2029 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Dostarlimab (DOSTARLIMAB) — full drug profile →
Conditions studied
- MMRd/MSI-H Stage II-III Endometrial Cancer — all drugs for MMRd/MSI-H Stage II-III Endometrial Cancer →
Sponsor
Grupo Español de Investigación en Cáncer de Ovario — full company profile →
Who can join
18 and older, female only, with MMRd/MSI-H Stage II-III Endometrial Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study for which participation is requested is a phase II clinical trial to assess the efficacy of dostarlimab as neoadjuvant therapy in patients with MMRd/MSI-H stage II-III endometrial cancer. The study is conducted in Spain with an estimated number of 25 patients for phase II. The main objective of this phase-II study is to evaluate the clinical complete response (cCR) after neoadjuvant therapy with dostarlimab.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Biology and evolving management of resectable dMMR/MSI-H cancers: current status and future perspectives.
Tanegashima T, Shiota M, Toyosaki K, Funakoshi K, et al · · 2025 · cited 1× · PMID 41196394 · DOI 10.1007/s00262-025-04223-9
Verify or expand the search:
- PubMed search for NCT07013851
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Dostarlimab
Trials testing the same drug.
- NCT07408063 — A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Res · Phase 2 · not yet recruiting
- NCT07381777 — XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Lo · Phase 2 · not yet recruiting
- NCT06405230 — Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Or · Phase 1, PHASE2 · recruiting
- NCT07336147 — Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine · Phase 2 · recruiting
- NCT07108270 — A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recur · Phase 2 · recruiting
Other Grupo Español de Investigación en Cáncer de Ovario trials
Trials by the same sponsor.
- NCT05728814 — DOstarlimab in Patients With Recurrent or dMMR/MSI-H Endometrial Cancer · unknown
- NCT05868889 — Retrospective Multicenter Study of Elderly Patients With Ovarian Cancer Treated With Trabectedin and PLD · completed
- NCT04546373 — Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer · completed
- NCT04539327 — Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study · completed
- NCT03598270 — Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07013851 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Grupo Español de Investigación en Cáncer de Ovario
- Last refreshed: 10 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07013851.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing